MétaCan
Menu
Back to cohort

Role of Recombinant Human Erythropoietin in Neonates with Moderate to Severe Hypoxic Ischemic Encephalopathy - A Prospective Cohort Study

2025· article· en· W4412838902 on OpenAlexvenueno aff
Chethan Nagaraju, Ravindra G. Naganoor, Siddu Charki, Mallanagouda M Patil

Bibliographic record

VenueInternational Journal of Child Health and Nutrition · 2025
Typearticle
Languageen
FieldMedicine
TopicNeonatal and fetal brain pathology
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineErythropoietinEncephalopathyProspective cohort studyRecombinant DNACohortHypoxic Ischemic EncephalopathyPediatricsIntensive care medicineInternal medicine

Abstract

fetched live from OpenAlex

Background: Hypoxic-ischemic encephalopathy (HIE) is a significant brain injury that occurs when there is inadequate oxygen supply to the brain during the neonatal period. Newer researches have established that rhEPO, human recombinant erythropoietin possesses neurological, neuro-restorative, and anti-inflammatory properties in asphyxia newborns. These effects are invaluable in enhancing outcomes for neonates diagnosed with hypoxic-ischemic encephalopathy-HIE Aims: To evaluate the role and effects of human recombinant erythropoietin in moderate to severe hypoxic-ischemic encephalopathy in neonates. Objective: To assess the safety and feasibility of rhEPO in asphyxiated neonates with moderate to severe encephalopathy. To know and to correlate the effect of EPO on EEG, RI (resistive index) in Neurosonogram (NSG), MRI brain in asphyxiated neonates with moderate to severe encephalopathy. Materials and methods: This is a Prospective Cohort Study conducted over 12-18 months with a sample size of 92, comprising 46 participants in each group. All neonates received intravenous recombinant human erythropoietin (rhEPO) after 6 hours of life. A total of 5 doses were administered. Results: In the EPO group, 47.8% (n = 22) had moderate encephalopathy, while 52.2% (n = 24) had severe encephalopathy. In our study we found that Amplitude–integrated electroencephalogram [aEEG] showed burst suppression [21.7% vs. 6.5%], low voltage [10.9% vs. 4.3%], flat trace [13.0% vs. 8.7%], and status epilepticus [6.5% vs. 2.2%] in the control group in comparison with EPO Group. A neurosonogram [NSG] was done and showed Abnormal RI [56.5% vs. 15.2%] and Normal RI [43.5% vs. 84.8%] in the control group in comparison with the EPO Group. Brain magnetic-resonance imaging [MRI] done at discharge showed severe brain injury [32.6% vs. 8.6%] and regional-specific HIE [19.5% vs. 39.1%] in the control group in comparison with the EPO Group. Mortality outcome was 10.8% in control group in comparison with EPO Group(2.17%). Conclusion: The study concludes that administering recombinant human erythropoietin (rhEPO) to newborns with moderate to severe hypoxic-ischemic encephalopathy (HIE) is safe and practical. In comparison to the control group, rhEPO treatment significantly reduces the occurrence of an abnormal resistive index (RI). Furthermore, EPO-treated neonates showed improvements in electroencephalographic (EEG) patterns, neurosonogram (NSG) resistive index, and MRI brain findings, suggesting possible neuroprotective advantages.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.006

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.001
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.005
GPT teacher head0.285
Teacher spread0.280 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueInternational Journal of Child Health and NutritionSame topicNeonatal and fetal brain pathologyFrench-language works237,207